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Urothelial carcinoma is the ﬁfth most common malignancy diagnosed each year in the United
States. Neoadjuvant and adjuvant chemotherapy are given to decrease the risk of recurrent or
metastatic disease with the more robust clinical data supporting the former. Bladder preservation
utilizes a trimodality approach with maximal transurethral resection followed by concurrent chem-
otherapy and radiation and is appropriate for select patients. Gemcitabine and cisplatin is the
current standard of care for ﬁrst-line treatment in ﬁt patients with metastatic disease. Optimal
second-line therapy remains undeﬁned, and targeted agents are under investigation. Clinical trial
participation should be encouraged in patients with urothelial carcinoma of the bladder to help
improve treatment regimens and outcomes. Synopsis. Chemotherapy is commonly used in the
treatment of urothelial carcinoma of the bladder. This paper will review the role of chemotherapy
in the neoadjuvant, adjuvant, bladder sparing, and metastatic settings.
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1. INTRODUCTION
Urothelial carcinomaisthe ﬁfth mostcommonmalignancydiagnosedin the UnitedStateswith anestimated
70,530 new cases and 14,680 deaths per year [1]. Approximately 30% of patients present with muscle
invasive urothelial carcinoma of the bladder (UCB) [2] and 5% have metastatic disease at presentation.
Radicalcystectomy is the usualtreatment of choice for muscle-invasivebladder cancerin the United States,
although bladder sparing approaches have gained ground in recent years. Despite adequate local control,
the overall survival (OS) after local therapy for muscle invasive UCB is suboptimal with ﬁve-year OS rates
for pathologic T2 disease of 52–77%, T3 disease 40–64%, and T4 or node-positive disease 26–44% [3].
Most patients who succumb to bladder cancer ultimately die due to distant disease. Thus, micrometastatic
disease at time of local therapy is a major challenge. The role of systemic therapy is reviewed here in four
contexts: neoadjuvant, adjuvant, bladder sparing with radiation, and metastatic disease.
2. NEOADJUVANT CHEMOTHERAPY
Integration of chemotherapy with surgery has been a dominant paradigm in oncology for decades,
improving cure rates in common epithelial neoplasms such as breast and colon cancer as well as rarer
mesenchymal tumors such as osteosarcoma and Ewing sarcoma. Progress in genitourinary cancers has
been slower. Neoadjuvant(presurgical) chemotherapyoffers potential advantagesoveradjuvanttherapy, for
example, early treatment of systemic micrometastases, potential downstaging of the primary and regional
disease, and an in vivo assessment of chemosensitivity. The neoadjuvant approach also avoids potential
delay in systemic treatment due to postoperative complications. This is a particular problem in bladder
cancer, where as many as 58% of patients may have postsurgical complications after radical cystectomy
[15], potentially preventing timely administration of chemotherapy.
Several studies have evaluated the role of neoadjuvant chemotherapy in muscle-invasive UCB. The
two most inﬂuential trials are discussed ﬁrst. In November 1989, the Medical Research Council Advanced
BladderCancerWorking Party andthe Genitourinary Group of the EuropeanOrganisationfor Researchand
Treatment of Cancer (EORTC) initiated an international study which randomized 976 patients with clinical
T2 grade 3, T3-4a, N0-Nx tumors who were undergoing either cystectomy or deﬁnitive radiation therapy
to receive 3 cycles of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) or no chemotherapy.
Although originally reported as a negative trial [16], with longer followup a statistically signiﬁcant survival
advantage emerged [17]. There was a 5.5% absolute difference in 3-year survival, and median OS for
the chemotherapy group was 44 months versus 37.5 months in the control group. Pathological complete
responses (CR) were signiﬁcantly higher (32.5% versus 12.3%) in the neoadjuvant chemotherapy group.
They reported a chemotherapy mortality of 1% while operative mortality was equivalent in the two groups.
The interpretation of these data are limited somewhat by the inclusion of both cystectomy and radiation-
treated patients.
The US Intergroup Trial (SWOG 8710) randomized 307 patients with T2-T4a UCB to surgery alone
or 3 cycles of neoadjuvant methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) [18]. With a
median followup of 8.7 years, risk of death was 33% greater in those treated with surgery alone (hazard
ratio 1.33). The median survival was 77 months in the chemotherapy group compared to 46 months with
surgery alone. Thirty-eight percent of patients treated with preoperative MVAC had a pathological CR at
surgery versus 15% in the surgery-alone group. Of those patients with a pT0 at surgery, 85% were alive at 5
years. Of note, this trial took 11 years to fully accrue,no doubt a record and indicative of the greatest hurdle
to progress in bladder cancer.
The Nordic Urothelial Cancer Group combined the results of two trials to evaluate cisplatin-based
combination neoadjuvant chemotherapy on 620 patients with T1 grade 3, T2-T4aNx bladder tumors [19].
The chemotherapy was cisplatin with doxorubicin in one study and cisplatin and methotrexate in the other.
With a median followup of 4.7 years, an 8% absolute risk reduction in death at 5 years was observed, with
an OS hazard ratio of 0.80 in favor of neoadjuvant therapy.
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Two meta-analyses of randomized trials of neoadjuvant chemotherapy for muscle-invasive bladder
cancer have been published. The Advanced Bladder Cancer Meta-Analysis Collaboration used individual
data from 3005 patients in 11 trials and reported a 5% absolute survival improvement at 5 years with plat-
inum-based combination neoadjuvantchemotherapy[20]. All but 196 patients received cisplatin [21]. They
also demonstrated a 9% improvement in 5-year disease-free survival (DFS). A similar outcome was seen
in another meta-analysis with an absolute OS beneﬁt of 6.5% (from 50 to 56.5%) at 5 years [22]. Mortality
attributed to neoadjuvant chemotherapy in this analysis was 1.1%.
Based on the data from the metastatic setting where gemcitabine and cisplatin (GC) has replaced
MVAC as preferred treatment due to similar responserates and reduced toxicity, GC has been studied in the
neoadjuvant setting in small, nonrandomized trials. Herchenhorn et al. reported a single institution study
with 3 cycles of neoadjuvant GC in 22 patients with T2-T4 disease and found a combined partial and com-
pleteradiographicresponsein70%ofpatients[23].PathologicCRwasfoundin26.7%(4/15)ofthepatients
who went onto surgery. Treatment was well tolerated with no deaths attributed to chemotherapy. With 26
month followup, the estimated median OS was 36 months. In a retrospective review from the Memorial
Sloan-KetteringCancerCenter,42patientswere treatedwith 4 cyclesofneoadjuvantGC,with downstaging
to pT0 in 26% of patients and to no residual muscle-invasive disease (<pT2) in 36% [24]. All the patients
achieving <pT2 remained disease-free at the median followup of 30 months. However, despite widespread
adoption, neoadjuvant GC has not been validated in prospective, randomized studies.
Overall, the data indicate that neoadjuvant cisplatin-based chemotherapy is feasible and provides a
modest survival beneﬁt. Therefore, it is appropriate to consider neoadjuvant chemotherapy as a standard of
care in muscle-invasive bladder cancer planned for surgical intervention.
3. ADJUVANT CHEMOTHERAPY
Postoperativeadjuvantchemotherapyis anothersystemictreatment optionfor patientswith muscle-invasive
bladder cancer. Immediate surgical intervention provides debulking and relief of local symptoms. Another
advantage is the availability of pathologic staging to more accurately assess risk, as clinical staging is often
inaccurate. A large case series of 3393 patients with UCB treated with radical cystectomy reported clinical
understaging in 50% of patients and pathologic downstaging in 18% [25].
Several trials have examined the role of adjuvant chemotherapy in muscle-invasivediseasewith con-
ﬂicting results. A trial with single-agent cisplatin failed to show a survival advantage [26]. Skinner et al.
reported91patientswith pT3-4ornode-positiveUCBrandomizedto adjuvantchemotherapy(predominant-
ly cisplatin, doxorubicin, and cyclophosphamide) versus cystectomy alone [27]. They found a signiﬁcant
improvement in time to progression with chemotherapy but no difference in 5-year OS. However, 25% of
patients randomized to adjuvant chemotherapy never received treatment. Another limitation of this study
was the variability of chemotherapeutic regimens.
Adjuvant MVAC or MVEC (with epirubicin instead of doxorubicin) was studied in 49 patients with
pT3-4a or positive lymph nodes using 3 cycles of chemotherapy after cystectomy and demonstrated im-
proved DFS at an interim analysis, resulting in the trial being stopped early [28]. It is important to note
that only 18 of the 26 patients randomized to the chemotherapy group received adjuvant treatment. The re-
sults were updated severalyears later with an additional 117 nonrandomizedpatients andcontinuedto show
a progression-freesurvival(PFS) advantagefor thosewhoreceivedadjuvantchemotherapy[29]. This group
also published long-term survival data on the initial 49 patients with a median followup of 160 months
[30]. In an intent-to-treat analysis, the median PFS was 66.9 versus 11.6 months (hazard ratio 2.84,
P = 0.002 favoring adjuvant chemotherapy) and tumor-speciﬁc survival of 71.8 versus 20.4 months with a
hazard ratio of 2.52 (P =0.007) favoring adjuvant treatment. Five-yearOS was 38.5% in the treatment arm
versus 17.4% in the control arm. Forty-four percent of patients in the control arm did receive combination
chemotherapy at progression.
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Adjuvant cisplatin and methotrexate (CM) was compared to MVEC in a phase III trial with 327
patients with pT3a-4a tumor or node-positive UCB [31]. Similar 5-year PFS, tumor-speciﬁc survival, and
OS rates were reported, but with signiﬁcantly reduced hematologic toxicity in the CM arm.
Trials such as these are often criticized for small sample sizes and lack of statistical power. Another
common criticism is that several studies were closed early after interim analyses. Two meta-analyses on
adjuvant chemotherapy for muscle invasive bladder cancer have been reported. The Advanced Bladder
Cancer Meta-Analysis Collaboration obtained individual patient data from 491 patients in 6 randomized
trials of adjuvant cisplatin-based chemotherapy and found an overall hazard ratio for survival of 0.75 (P =
0.019) favoring adjuvant therapy [32]. This corresponds to an absolute improvement in survival of 9% at 3
years. However, the lack of robustnessof the data preventedthe authors from making a formal endorsement
of adjuvant treatment. Another meta-analysis of 5 trials found a similar improvement in OS with adjuvant
chemotherapywith a hazardratio of 0.74(P =0.001)[33]. Svatek etal. reported retrospectivedata from 11
centers with 3947 patients with high-risk UCB treated with cystectomy, of which 23.6% received adjuvant
chemotherapy [34]. Adjuvantchemotherapy was associated with improved survival(hazard ratio 0.83, P =
0.017) with increasing beneﬁt seen with higher-risk subgroups.
Several other large randomized trials have been reported in abstract form. An Italian group random-
ized 194 patients with pT2 grade 3, pT3-4, N0-2 UCB to adjuvant GC versus chemotherapy at relapse
and did not show a signiﬁcant difference in DFS and OS [35]. However, the trial closed early due to poor
accrual, enrolling only 32% of the target sample size. A US study randomized 114 patients with pT1-2, N0,
p53 positive tumors to 3 cycles of adjuvant MVAC or observation [36]. Further accrual was halted after a
planned interim futility analysis showed no signiﬁcant differences in recurrence-free survival. Only 67%
of patients randomized to MVAC received all 3 cycles, and 12% received none, further limiting the power
of the study. The Spanish Oncology Genitourinary Group (SOGUG) 99/01 study also closed prematurely
due to poor recruitment after 7 years and failure to meet goal enrollment of 340 patients. They randomized
142 patients with pT3-4 or node-positive disease to 4 cycles of paclitaxel, gemcitabine, and cisplatin (PGC)
versus observation. With median follow up of 51 months, a 5 year OS beneﬁt with chemotherapy of 60%
versus 31% (P < 0.0009) was reported [37].
The EORTC 30994 phase III trial comparing immediate versus deferred chemotherapy (MVAC,
high-dose MVAC every 14 days with growth factor support, or GC) after radical cystectomy in patients
with pT3-4 or node-positive UCB planned to enroll 660 patients but closed after 7 years with only 284 ac-
crued [38]. No results have been reported as of yet. Similarly, Cancer and Leukemia Group B (CALGB)
90104 intended to compare sequential doxorubicin and gemcitabine followed by paclitaxel and cisplatin
with GC alone in the adjuvant setting, but closed due to slow accrual after enrolling only 42 subjects.
While data from meta-analyses suggest a possible beneﬁt to adjuvant chemotherapy in muscle
invasive UCB, further data are needed before ﬁrm recommendations can be made. Available clinical trial
data are underpowered and more recent attempts at large randomized trials have accrued poorly. Possible
contributors to this phenomenoninclude the frequent occurrence of postoperative complications preventing
adjuvant treatment, the frequent coexistence of chronic kidney disease in this population limiting the use of
cisplatin, and lack of interest on the part of urologists, medical oncologists, and/or patients. In the absence
ofrobustdata,mostGU oncologistsoffer adjuvanttherapyto ﬁtpatientswhenneoadjuvanttherapyis notan
option. Whether this should also be done for patients not suitable for cisplatin is an even murkier question.
Ongoing clinical trial participation is essential, but the ﬁeld lacks momentum at this point in time.
4. CHEMOTHERAPY IN BLADDER PRESERVATION
Bladder preservation may be accomplished in appropriately selected patients with muscle-invasive UCB
without compromising outcomes using a trimodality approach with maximal transurethral resection (TUR)
followed by concurrent chemotherapy and radiation therapy. Optimal application of this approach re-
quires close coordination among the urologist, medical oncologist, and radiation oncologist. Appropriate
candidates have T2-4a and clinically node-negative disease, primary tumors amenable to complete or near
1984TheScientiﬁcWorldJOURNAL (2011) 11, 1981–1994
complete TUR, no hydronephrosis and adequate renal function to tolerate cisplatin. Salvage cystectomy is
required for persistent or recurrent disease at repeat cystoscopy, either during or after chemoradiotherapy
(CRT), and is typically necessary in approximately one-third of patients [39]. The largest single-institution
series from the University of Erlangen (415 patients) showed that early tumor stage and a complete TUR
are the most important factors predicting CR and survival [40]. Chemotherapy alone is not an appropriate
treatment for muscle-invasive UCB being treated for cure.
Two randomized trials have shown that concurrent CRT is more effective than radiation alone in
reducing local recurrences, but an improvement in OS has not yet been demonstrated [41, 42]. There are
no prospective randomized trials of CRT versus cystectomy. Thus, knowledge of this approach is derived
primarily from case series and phase I/II trials.
The largest US series comes from the Massachusetts General Hospital. They have reported on 190
patients using concurrent cisplatin-containing chemotherapy and radiotherapy after TUR [43]. Surgical
candidateswith lessthanacT0responseto CRTorthoseunabletotolerate CRTwenttosalvagecystectomy.
With a median followup of 6.7 years, the 5- and 10-year disease-speciﬁc survival rate was 63% and 59%
with the 5- and 10-year disease-speciﬁc survival rate for patients with an intact bladder of 46% and 45%,
respectively. The pelvic failure rate was 8.4%. One-third of patients treated on protocol with the goal of
bladder sparing ultimately required a cystectomy.
The concept of induction chemotherapy in bladder preservation has been explored by the Radiation
Therapy Oncology Group (RTOG) in serial phase II studies. RTOG 89-03 randomized 123 patients with
T2-4a, Nx UCB to 2 cycles of neoadjuvant cisplatin, methotrexate, and vinblastine (CMV) followed by
concurrent CRT with cisplatin versus concurrent CRT with cisplatin alone; those with less than CR at
cystoscopy underwent cystectomy and those with a CR underwent additional CRT [44]. Seventy-four
percentcompletedthetreatment,andtherewasnosigniﬁcantdifferencein5-yearOS,OSwithafunctioning
bladder, freedom from metastatic disease, freedom from pelvic recurrence, or improvement in clinical CR
rate. Thus, the role of induction chemotherapy has not been established.
Other chemotherapeutic agents have been evaluated with and without cisplatin to enhance
radiosensitivity. Zietman et al. described 18 patients with T2-4a UCB treated with twice daily radiation
with cisplatin and 5-ﬂuorouracil (5-FU) [45]. Of note, 15 of the patients were also treated with adjuvant
CMV. A complete response to CRT was seen in 14 of 18 patients, the 3-year OS was 83%, and the 3-
year survival with a native bladder was 78%. One hundred twelve patients with muscle-invading or high-
risk T1 UCB were enrolled in a study of concurrent cisplatin and 5-FU with radiotherapy that reported
5 year overall and cause-speciﬁc survival for all patients of 74% and 82%, respectively, [46]. Eighty-eight
percent of patients had a CR, and, of all surviving patients, 82% maintained their own bladder.RTOG 95-06
evaluated 34 patients with clinical stage T2-4a, Nx UCB treated with twice daily radiation with cisplatin
and 5-FU with an induction course followed by consolidation if a CR was achieved [47]. With a median
followup of 29 months, 67% of patients had a CR after induction treatment, and the actuarial 3-yearOS was
83% with 66% of patients surviving with an intact bladder. However, 21% of patients developed grade 3-4
hematologic toxicity during therapy.
RTOG 99-06 evaluated80 patients with T2-4a UCB treated with twice daily radiation with paclitaxel
and cisplatin (induction CRT) [48]. If repeat biopsy showed <T1 disease, they were treated with consolida-
tion chemoradiotherapy; if >T1, then cystectomy was advised. All patients received adjuvant GC. Ninety-
ﬁve percent completed the induction treatment with 26% grade 3-4 toxicities. The postinduction CRT com-
plete responserate was 81%. AdjuvantGC was completed in 70%of patients with grade 3 toxicities in 46%,
grade 4 in 26%, and 1 death due to thrombotic thrombocytopenia purpura and hemorrhagic stroke. With a
median followup of 49.4 months, the 5-year OS rate was 56%, and disease-speciﬁc survival rate was 71%.
RTOG 97-06 also looked at twice daily radiation but added adjuvant CMV chemotherapy [49]. They
described47 patients with T2-4a, N0 UCB after TUR treated with induction CRT with twice daily radiation
with cisplatin. If there was no evidenceof diseaseat repeatcystoscopy,they were treated with consolidation
CRT. Patients with residual tumor went onto cystectomy. After either consolidation CRT or cystectomy,
patients were treated with 3 cycles of CMV chemotherapy. The CR rate after induction therapy was 74%.
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The projected 3-year OS and bladder-intact survival was 61% and 48%, respectively. However, only 45%
of patients completed three cycles of adjuvant chemotherapy.
Gemcitabine as a radiosensitizer has been shown to be well tolerated and feasible in UCB in early-
phase trials [50, 51]. A Phase II trial of concurrent weekly gemcitabine with radiation was reported in 50
patients with T2-3 UCB with 92% of patients tolerating 4 doses of gemcitabine and 88% achieving a CR
[52]. At a median followup of 36 months, the 3-year cancer-speciﬁc survival was 82% with OS of 75%.
Eighty-nine percent of survivors had intact bladders. There was no difference in late toxicity scores at 2
years as compared to baseline.
In appropriately selected patients, bladder preservation with TUR, chemotherapy, and radiation are
feasibleandproduceshigh rates ofCR with acceptablediseasecontrolandOS with intactbladders.Concur-
rent cisplatin-based radiation has the most supporting data, but newer agents are being evaluated.The value
of induction chemotherapy has not been established, and the value of postradiation adjuvant therapy, while
conceptually attractive, lacks sufﬁcient data for deﬁnitive conclusions. Careful, continued surveillance with
cystoscopy both during and after CRT is mandatory.
5. METASTATIC DISEASE
UCB is considered a chemotherapy-sensitive disease with response rates in ﬁt patients approaching 50%.
Systemic chemotherapy remains the standard of care for patients with metastatic UCB. The principle chal-
lengein thiscontextis thehighfrequencyofimpairedperformancestatus,renaldysfunction,andothercom-
orbidities.
Historically, the standard ﬁrst-line therapy for ﬁt patients in the combination chemotherapy era has
been MVAC. MVAC has been compared to both cisplatin alone and a combination of cisplatin, cyclophos-
phamide, and doxorubicin (CISCA) with superior response rates and OS [53, 54], with median survival
of 12.5 months [53]. However, MVAC is associated with signiﬁcant toxicity including myelosuppression,
neutropenic fever and sepsis, mucositis, nausea, vomiting, and a 3-4% toxic death rate [53, 55]. These
side effects and the complex schedule often limit its use. However, 3.7% of patients randomized to MVAC
in one trial were alive and disease-free at 6 years, indicating it may be curative in a small fraction of
patients [56]. EORTC 30924 studied standard MVAC versus dose-intensiﬁed MVAC with growth factor
support (HD-MVAC) in an attempt to improve outcomes as well as decreasetoxicity. A total of 263 patients
were randomized and, while there was no statistically signiﬁcant difference in response rates or OS, there
was borderline improved PFS (9.1 versus 8.2 months) as well as less leukopenia, neutropenic fever, and
mucositis with HD-MVAC [55].
Due to signiﬁcant toxicities with MVAC, other regimens have been investigated in the ﬁrst-line
metastatic setting. A phase III trial of 220 patients demonstrated that MVAC was more effective than doce-
taxel and cisplatin with improved response rates, time to progression, and median survival [57]. After en-
couraging phase II data [58–60], gemcitabine and cisplatin (GC) were compared to MVAC in a randomized
phase III trial with 405 patients [61]. While the study was not powered to show equivalency, overall
response rate, time to progression, and median survival were similar for both regimens, with less grade 3-4
neutropenia, neutropenic fever, sepsis, mucositis and alopecia in the GC arm. The toxic death rate was 3%
with MVAC and 1% with GC. Long-term followup after 5 years demonstrated continued similar survival
between the two arms [62]. Based on these results, GC is now considered the standard-of-care ﬁrst-line
therapy for ﬁt patients with metastatic bladder cancer.
Attempts to improve upon this regimen have included adding a third drug to GC. The SOGUG
found the combination of paclitaxel, gemcitabine, and cisplatin (PGC) to be feasible with an overall re-
sponse rate of 77.6% (with 28% CRs) in 61 patients [63]. To more fully evaluate this tactic, the EORTC
30987/Intergroup Study randomized 627 patients to either PGC or GC with a primary endpoint of OS [64].
The ﬁrst report in abstract form demonstrated an improved response rate with PGC (57% versus 46%) but
only a trend in favor of OS (15.7 versus 12.8 month, P = 0.10). Of note, the study was powered to detect
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a 4-month difference in survival. There was more thrombocytopenia on the GC arm, while PGC was asso-
ciated with increased leukopenia, neutropenia, and febrile neutropenia.
The role of carboplatin has been evaluated in both cisplatin eligible and ineligible populations.
Several studies have compared carboplatin- and cisplatin-containing regimens in patients with adequate
renal function. A phase II trial in 55 patients comparing MVEC versus MVECa (methotrexate, vinblastine,
epirubicin, and carboplatin) demonstrated that MVEC had higher response rates compared to the
carboplatin-containing regimen [65]. Bellmunt et al. reported 47 patients randomized to MVAC or MCAVI
(methotrexate, carboplatin, vinblastine) and showed that MCAVI was less toxic but also less effective with
median DFS favoring MVAC (16 months versus 9 months) [66]. An Eastern Cooperative Oncology Group
(ECOG) study attempted to compare carboplatin and paclitaxel (CP) to MVAC, although median survival
wassimilar, thestudy closedprematurely dueto slow accrual[67], and no deﬁniteconclusionscanbemade.
GC was compared to gemcitabine and carboplatin in a phase II study in 110 patients with the primary ob-
jectiveto comparetoxicities[68]. Toxicitiesweresimilar, andmediansurvivalwasnotsigniﬁcantlydifferent
at 12.8 monthsin the GC arm versus9.8 months in the gemcitabine/carboplatinarm, although the study was
inadequately powered for this endpoint. Based on this evidence, cisplatin remains the standard of care in
patients with adequate renal function.
In patients unﬁt for cisplatin, carboplatin-based regimens have demonstrated activity [69–73]. How-
ever, there is signiﬁcant variability in the deﬁnition of patients “unﬁt” for cisplatin. A recent abstract re-
viewed 14 publications regarding cisplatin ineligibility and noted wide variation in terms of renal function,
performance status, age, and comorbidities [74]. The authors proposed a consensus deﬁnition of cisplatin
ineligibility criteria for clinical trials including (1) ECOG performance status of 2, (2) creatinine clearance
<60mL/min, (3) Common Terminology Criteria for Adverse Events (CTCAE) Grade ≥2h e a r i n gl o s s ,( 4 )
CTCAE Grade ≥2 neuropathy. Also confounding the problem is the fact that current formulas estimating
creatinine clearance tend to underestimate the measured creatinine clearance, especially in those patients
older than 65 years [75].
First-line nonplatinum combinations have been evaluated in phase II trials and have shown activity
with response rates of 54–70% with gemcitabine and paclitaxel [76, 77]. In one series of 36 patients, 14%
developed grade 3–5 pulmonary toxicity [77]; however this degree of pulmonary toxicity was not seen in
other trials [76, 78, 79] and has not been an issue with this regimen in lung cancer patients [80]. A phase II
trial of 46 patients treated with pemetrexed (a multitargeted antifolate agent) and gemcitabine demonstrated
a response rate of 32% and a median OS of 12.4 months [81]. However, this was at the expense of 75%
grade 3-4 myelosuppression. There are no reported phase III comparisons of nonplatinum regimens.
Several single agents have been evaluated in the second-line setting in phase II trials (Table 1). As
one might expect, the problem of “unﬁt” patients is even more challenging in this context. Single agents
including ifosfamide [4], docetaxel [5], and gemcitabine [6, 7] have been evaluated in small studies with
modest results.Second-line weekly paclitaxelhas a low responserate [8, 9], though onestudy reported 38%
with stable disease [9]. Pemetrexed has been reported to have a response rate of 28%, a median OS of 9.6
months and was well tolerated in a phase II trial of 47 pretreated patients [10]. However,anotherstudy of 13
patients only showed a 8% response rate [11]. Single-agent ixabepilone also has modest activity [12]. An
encouraging phase II trial of second-line nab-paclitaxel was recently presented, reporting a response rate of
33% with a 58% clinical beneﬁtr a t e[ 13]; this is deserving of further investigation.
Vinﬂunine is a novelmicrotubule inhibitor that has been studied in a phase III trial in the second-line
setting for metastatic UCB, where 370 patients were randomized to vinﬂunine plus best supportive care
versus best supportive care alone [14]. In the eligible population of 357 patients, the median OS was
signiﬁcantly longer for the vinﬂunine group (6.9 versus 4.3 months). Grade 3-4 toxicities included neutro-
penia (50%), febrile neutropenia (6%), anemia (19%), fatigue (19%), and constipation (16%). There was
one drug-related death on study. Vinﬂunine is approved for use in Europe but not in the United States.
Second-line combination therapies have also been evaluated. Two phase II trials looked at various
dosesofgemcitabineandpaclitaxelin platinum-pretreatedpatients,with responseratesof30%and33%and
median survival of 11.5 and 11.3 months, respectively [82, 83]. A phase III trial of 102 patients compared
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TABLE 1: Second-line single agent chemotherapy trials in advanced urothelial carcinoma.
Reference Agent Subjects Response rate (%) Survival (months)
Witte et al. [4] Ifosfamide 56 20 5.5
McCaffrey et al. [5] Docetaxel 30 13 9
Lorusso et al. [6] Gemcitabine 35 23 5
Albers et al. [7] Gemcitabine 30 11 8.7
Vaughn et al. [8] Paclitaxel 31 10 7.2
Joly et al. [9] Paclitaxel 45 9 7
Sweeney et al. [10] Pemetrexed 47 28 9.6
Galsky et al. [11] Pemetrexed 13 8 Not reported
Dreicer et al. [12] Ixabepilone 45 12 8
Sridhar et al. [13] Nab-paclitaxel 48 33 Not reported
Bellmunt et al. [14]V i n ﬂunine 307 9 6.9
“short term” treatment with weekly gemcitabine and paclitaxel in a 21-day cycle with a maximum of 6
cycles versus continuing the same treatment until disease progression [79]. There was no difference in
responserates (37.5 versus 41.5%) and OS (7.8 versus8 months) in the two arms; there was more grade 3-4
anemia and two treatment-related deaths in the prolonged treatment arm. The combination of ifosfamide
and docetaxel in 20 cisplatin-pretreated patients demonstrated an overall response rate of 25% including 4
CRs [84]. Given the lack of deﬁnitive randomized data, there remains no well-deﬁned standard of care for
second-line chemotherapy for metastatic bladder cancer.
6. NOVEL AND TARGETED AGENTS
Her2/neu is variably expressed on urothelial carcinomas and has been evaluated as a possible therapeutic
target. One study screened 109 patients with advanced UCB and found that Her2-positive patients (52%)
had more metastatic sites and higher rates of visceral disease than Her2-negative patients [85]. Forty-four
patients were treated with trastuzumab, paclitaxel, carboplatin, and gemcitabine with an overall response
rate of 70% with 57% conﬁrmed responses. Median survival was 14.1 months. Toxicities included 93%
grade 3-4 myelosuppression, 14% grade 3 sensory neuropathy, 22.7% grade 1–3 of cardiotoxicity (4.5%
grade 3), and 3 therapy-related deaths.
Table 2 summarizes the ongoing clinical trials with targeted agents in urothelial carcinoma. Epider-
mal growth factor receptor (EGFR) expression has been demonstrated on 50% of bladder tumors [86], and
trials are ongoing with cetuximab. Vascular endothelial growth factor (VEGF) receptors are another poten-
tial target. Trials are evaluating the use of bevacizumab both in the metastatic and neoadjuvant setting as
well as other anti-VEGF agents.However,a recent phaseII experiencewith sunitinib in advancedUCB was
disappointing, with only 4 responses in 77 patients [87].
Given the experience in nonmuscle-invasive UCB with BCG and interferon, there has been interest
in the application of immunotherapy to more advancedbladdercanceras well. Ongoingtrials are evaluating
a human chorionic gonadotropin-β vaccine (Celldex Therapeutics, CDX1307-03, NCT01094496), and
the anticytotoxic T-lymphocyte-associated antigen 4 antibody ipilimumab (NCT00462930), both in the
neoadjuvant setting.
7. CONCLUSIONS
Chemotherapy continues to play an important role in the treatment of urothelial carcinoma in a variety of
settings. Neoadjuvant cisplatin-based combination chemotherapy has demonstrated a small but signiﬁcant
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TABLE 2: Ongoing clinical trials with targeted agents in urothelial carcinoma.
Phase Cohort Subjects Treatment Protocol number
I/II
Noncystectomy candidates
undergoingradiation in
muscle-invasive disease
88 Paclitaxel ± trastuzumab NCT00238420
I First line metastatic/advanced 25 GC with lapatinib NCT00623064
II/III
Maintenance after ﬁrst-line
metastatic/advanced
204 Lapatinib versus placebo NCT00949455
II First-line metastatic/advanced 86 GC ± cetuximab NCT00645593
II First-line metastatic/advanced 51 GC with bevacizumab NCT00588666
III First-line metastatic/advanced 500 GC ± bevacizumab NCT00942331
II Neoadjuvant/adjuvant 25
NeoadjuvantGC with bevacizumab
Adjuvant paclitaxel with
bevacizumab
NCT00268450
II Neoadjuvant 45 GC with sunitinib NCT00847015
II Adjuvant 33
Sunitinib (after neoadjuvant
platinum-based chemotherapy)
NCT01042795
II
First-line cisplatin ineligible
metastatic/advanced
41 Sunitinib NCT01118039
II First-line metastatic/advanced 63 GC with sunitinib NCT01089088
II Neoadjuvant 45 GC with sorafenib NCT01222676
II First line metastatic/advanced 30 GC with sorafenib NCT00461851
I
Non-cystectomy candidates
undergoingradiation in muscle
invasive disease
18 Sorafenib NCT00544609
II
Second-line cisplatin pretreated
metastatic/advanced
41 Pazopanib NCT01031875
II Second- or third-line metastatic 32 Pazopanib with weekly paclitaxel NCT01108055
Pilot Neoadjuvant 25 Dasatinib NCT00706641
II
First-line cisplatin ineligible
metastatic/advanced
122
Carboplatin/Gemcitabine±
vandetanib
NCT01191892
∗Data from http://www.clinicaltrials.gov/ accessed on April 2011.
survival beneﬁt. Adjuvant chemotherapy can also be considered, although the data are less compelling. A
bladder-sparingapproachusingchemoradiotherapyisappropriatein carefullyselectedpatients.Chemother-
apy remains the mainstay of treatment of metastatic urothelial carcinoma. Gemcitabine plus cisplatin is the
current standard of care for ﬁrst-line treatment in ﬁt patients. Data are less robust for patients unﬁtf o rc i s -
platin, but carboplatinis often used.Thereare no conclusivedatato supporta standardsecond-lineregimen,
andcurrentpracticereliesonphaseIItrials.Varioustargetedagentsarecurrentlyunderinvestigation.Devel-
opment of less toxic, more effective agents is critical, and clinical trial participation needs to be prioritized.
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